Embed Size (px)
Citation preview
1
Audrey’s Life Science Meeting Picks for Oct. 9, 2016 – November 2016
Complimentary Service of AudreysNetwork.com
Oct. 9, 2016 *******************************************************************************************
Bio2Device Group, Tuesday Evening, Oct. 11, 2016
Topic: Polymers as drugs and the Development of Veltassa
Speaker: Dr. Steve Harrison, SVP of Research, Relypsa
Date and Time: Tuesday, Oct. 11, 2016, 6-9 pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins (as space permits)
Register at www.Bio2DeviceGroup.org
Topic Description
Relypsa has been focused on the development of polymer therapeutics for more than 10
years, and has developed a technology platform for the high throughput synthesis,
evaluation, and optimization of novel polymers. This technology has been applied to the
discovery and development of orally available, nonabsorbed polymers which display
selective binding capability in the GI tract. Our program has resulted in the generation of
multiple polymer therapeutics for the treatment of serious conditions, including patiromer,
which was approved in the United States in late 2015 as Veltassa™ for the treatment of
hyperkalemia. Patiromer is a novel, spherical, nonabsorbed polymer designed to bind and
remove potassium, primarily in the colon, thereby decreasing serum potassium in patients
with hyperkalemia, a potentially life-threatening condition.
Relypsa’s platform for polymer discovery and optimization will be described, including its
application to targeted therapeutic polymer development. This potential will be illustrated
with reference to Veltassa.
Speaker Bio
Stephen joined Relypsa in December 2014 with 20 years’ tenure in biotechnology and
pharmaceutical discovery and development. A biochemist and molecular biologist, he is
highly published and has extensive experience leading product-driven research
organizations at all stages, from target identification to early clinical development. Prior to
joining Relypsa, Stephen was vice president, Research Biology at Nektar Therapeutics, a
leader in polymer conjugate therapeutics, where for four years he managed global oncology
and pain research efforts. Prior to Nektar, he was senior vice president, Research at KAI
Pharmaceuticals, a company focused on peptide modulators of protein interactions. While at
KAI, Stephen generated one development candidate per year and led discovery efforts,
including the company's lead compound for the treatment of secondary
hyperparathyroidism, which served as the basis for the company's eventual acquisition by
Amgen. Earlier in his career, Stephen held senior research positions at Chiron Corporation
and Thios Pharmaceuticals. He holds a Ph.D. in Molecular Biology, a M.A. and B.A. in
Biochemistry all from University of Cambridge, England.
****************************************************
Consensia, Thursday Morning, Oct. 13, 2016
2
Topic: “A New Paradigm for Medical Device Development Lean-Agile Software and Hardware
Development Methodology”
Date and Time: Thursday Morning, Oct. 13, 2016, 8:00 am- 10:00 am
Location: Dassault Systèmes Welcome Center, 3979 Freedom Circle, Suite 750 Santa Clara
95054
Program
• Introduction-Sanjay Keswani, CEO, Consensia
• Innovative Product Design with Agile Methods
Roger Tang, Ph.D., Principal, H R Tang Consulting
• Accelerating Medical Device Development while Improving Compliance
Aaron Joseph, Senior Consultant, Irwin and Associates
No charge for free breakfast seminar
Register at Follow this link for more information and registration for the breakfast seminar:
http://consensiainc.com/md-seminar/
Event Description
Consensia, a channel partner of Dassault Systemes, cordially invites you to attend a FREE
Breakfast Seminar to learn about lean and agile development, and how it enables medical
device companies to accelerate product development. Companies in multiple industries have
found that lean and agile methods speed up their product development while simultaneously
improving quality and cutting costs. Medical device companies can also take advantage of
lean and agile methods if they understand how to adapt them to a regulated environment
and how to modify their quality systems to support the new approach to product
development.
This interactive seminar will provide insights into how lean and agile methods address these
common problems in medical device development:
Design flaws discovered late in development leading to expensive delays
Schedule overruns with software development
Compliance problems with design controls
Product recalls
High Manufacturing costs
We will cover the key principles behind lean and agile methods and then illustrate them in
more detail with a side-by-side comparison of two example projects—one utilizing lean and
agile methods and the other utilizing a traditional approach. The seminar will conclude with
a discussion of how to modify design controls, risk management, and other quality system
procedures to support lean and agile product development.
Follow this link for more information and registration for the breakfast seminar:
http://consensiainc.com/md-seminar/ **********************************************************************************************************
Biotech Bay Talent Connect, Monday Afternoon, Oct. 17, 2016
Event: Biotech Bay Talent Connect
Date and Time: Monday, October 17, 2016, 4:00 pm- 7:00 pm
Location: South San Francisco Conference Center-255 South Airport Boulevard South San
Francisco
Event Description
Talent Connect is a new level of Life Sciences networking. Make meaningful connections
with peers, HR representatives, recruiters and hiring managers from top biotech, pharma,
medical device and diagnostics companies.
3
Who should attend?
All Life Sciences professionals are invited to attend, including PhD and Postdoc candidates
as well as professionals with Life Sciences experience in any discipline. Your resume is
required to register.
What companies will be there?
A full list of companies will be posted here prior to the event. If you can’t make it on event
day but are willing to relocate to the area, you should still register a few days before the
event. Employers will be able to view your resume and know you’re interested.
What types of positions are available?
Employers are recruiting for positions in areas such as: QA/QC, clinical research,
engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory
affairs, project management, research and more. Click on the employers names to access
their open jobs posted on BioSpace. We highly recommend researching each company
before you attend the event.
Resume is required to complete registration
Employers: Represent your company at Talent Connect
Are you looking to connect with top-tier Life Sciences candidates? Want to take your
employer branding to the next level? Contact us to reserve your company's space today at
(877) 277-7585 or email [email protected].
Not another career fair. A unique opportunity to network with peers, influencers and hiring
managers at the hottest biotech, pharma, medical device and diagnostics companies in an
open, inviting and enjoyable format.
Why attend?
Connect with some of the leading companies in Life Sciences such as Merck & Co, Abbvie,
and Dynavax.
Make meaningful connections with top Life Sciences companies at friendly, un-awkward
roundtables.
90% of people who attended Talent Connect events said they'd come again, so it was worth
their time. It'll be worth yours, too.
************************************************************************* JLABS Bay Area, Tuesday Morning, Oct. 18, 2016
Topic: “The Real Deal: How to Lead with Authenticity”
Presenter: John Bates | Chief Executive Officer & Executive Whisperer, Executive
Speaking Success & Business Coaching read bio»
Date and Time: Tuesday, October 18, 2016 from 11:00 AM to 1:30 PM (PDT)
Agenda:
11:00 AM | Registration Opens, Lunch, and Networking
11:45 AM | Presentations
12:30 PM | Discussion and Q&A
12:45 PM | Audience Participation - Pitches & Critique
1:30 PM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, CA
Fees:
$35 | General Public
$20 | Student/Academic
4
$45 | At the door
Topic Description
You are a leader - no question about that.
The only question is whether you know how powerful a leader you can be and
whether you are leading people in the most productive direction. If you would like to
know how you can benefit from one of the least understood, most feared, and deeply
underutilized leadership skills of all time, this is the workshop for you.
In this engaging, and eye-opening presentation, John K. Bates, a world renowned
Leadership Communications Expert, dives deep into the history of eye contact and
the value of authenticity in the workplace as a leader and as an employee, as well as
its value in everyday life.
John bases his work in Human Evolutionary Biology and Human Neurophysiology and
explains not only why authenticity is so difficult, but also why it is so meaningful, so
appreciated and why it is the only way to achieve true leadership success. John
shares stories from his own experiences as well as from those of people like top-
rated TED speaker Brene Brown and world famous public speaker Les Brown.
Practice makes perfect. A number of audience members will have an opportunity to
tell their 1 - 3 minute story with an immediate critique by Executive Whisperer and
coach, John Bates. Come ready to share a pitch, your personal introduction or a
portion of a speech you have coming up... and remember, we'll be looking for the
authentic side of whatever you share.
The "How to... Workshop" series is dedicated to giving you the keys to a successful
business, from creation to exit. As with all our events, the "How to... Workshop" is
interactive and informal so bring your questions with you!
Presenter’s Bio
John Bates | Chief Executive Officer & Executive Whisperer, Executive Speaking
Success & Business Coaching
John Bates has spoken, hosted and coached for over 22 different worldwide TED and
TEDx events. His group trainings are world famous and executives from companies
like Johnson & Johnson Innovation Labs, Accenture, Boeing, NASA, IBM, and more,
recommend him to their colleagues as the best communications and leadership
trainer working today.
Long ago John fell in love with the Internet the moment it dawned on him what it
would do for communication. Since then he has worked with early stage companies
as a Founder or early employee, has been instrumental in raising hundreds of
millions of dollars in Venture Capital and has always earned the title Chief Evangelist.
He Co-Founded BIGWORDS.com, a dotcom darling which ended up going bust in the
dotcom bomb of 2000, and he was the first employee and is a part owner of current
Internet powerhouse Goldstar.com.
John is a co-author of World Class Speaking in Action, an Amazon best-seller, and
loves making a difference for those who make a difference.
Connect with John:
About Executive Speaking Success:
Based in Los Angeles, California, Executive Speaking Success (ESS) is a global leader
in communication and leadership training. The firm's techniques are grounded in
evolutionary biology and human neurophysiology, revealing both what works in
5
communication as well as why it works.
The company's training style is dedicated to bringing out greatness in people and
companies so they can make a real difference in the world. ESS delivers its programs
all over the world working with C level executives, business development and sales
teams, keynote speakers, TED and TEDx speakers, as well as anyone who is
committed to being successful in their leadership and communications.
Founded in 2012, the company is led by John K. Bates, an internationally regarded
leadership communications trainer and keynote speaker, as well as a savvy
entrepreneur. Bates has been actively coaching since 2005, working with CEOs and
the executive teams of Johnson & Johnson Innovation Labs, the VW Electronics Lab,
Janssen Labs, DudaMobile, Motorola, Goldstar, Oculus International, LAZ Parking,
BigFra.me, Stone Brewing Co., and many others on their leadership, presentation,
media and business skills. Prior to his training career, he has been involved in
helping to found and start up Goldstar, BigWords.com (which raised over $80 mill ion)
and VirtualVegas the first online "destination site". He has raised hundreds of millions
of dollars in venture capital funds, successfully opened resistant markets for new
products and has run the customer service department for a multi-million dollar
company. Bates is also a contributing author to the book World Class Speaking in
Action: 50 Certified World Class Speaking Coaches Show You How to Present,
Persuade, and Profit which became a multiple Amazon best seller.
ESS programs entail a combination of large and small group training and one-on-one
training both online and in person. Programs can be customized based on needs and
budget.
****************************************************************
EMBS, Wednesday Evening, Oct. 18, 2016
Topic: "Surgical Robotics Development - From Research Lab to Commercialization"
Speaker: Jian Zhang, Ph.D., Co-Founder and Former CEO, RobotPhoenix
Wednesday, October 18, 2016, 7:30 PM
Location: Room M-114, Stanford University Medical School
Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations)
Topic Description
The talk will primarily focus on the development of a surgical robotics prototype for cochlear
implant surgery. Key design considerations and development process will be discussed.
Challenges in existing manual cochlear implant surgery will be addressed. Iterations of
engineering design and validations further improve the results in dry lab and in vitro study.
Key findings in the robot-assisted cochlear implant experiments will also be presented. A
comparison between research lab engineering development and corporate or start-up
engineering development will also addressed. Different design considerations and
procedures need to be followed and taken care of in order to later prepare the system for
animal or human studies.
Speaker Bio
Dr. Jian Zhang was the CEO and co-founder of RobotPhoenix, a venture backed startup in
China. During his tenure, the company developed a delta robot for packaging, from
prototype to production. The company raised 4 million dollars venture capital. In 2015, the
company’s revenue reached about 2 million dollars. Previously, he was the director of
system engineering and research at Auris Surgical Robotics, where he was part of the
founding engineering team (employee #2) and lead the early system development which
6
was used in First in Human studies. Auris has developed two generations of surgical robotics
systems and closed a total of 190 million dollars venture capital. The system also received
FDA clearance in 2016. Before joining Auris Surgical, he was part of the core engineering
team developing the da Vinci Xi Surgical System. Dr. Zhang received his M.S. M.Phil., and
Ph.D. degrees with distinction from Columbia University. His doctoral research “Robotic
Assistance to Cochlear Implant Surgery” was funded by the United States National Science
Foundation. His second research project on “High throughput automated minimally-invasive
radiation biodosimetry” was supported by the United States National Institute of Health. His
research has been reported by the Associated Press, New York Times, and Nature website.
Dr. Zhang co-authored one book chapter and more than 20 peer-reviewed journal and
conference papers. He’s been technical reviewer for IEEE Transaction on Robotics (IEEE
TRO), the International Conference on Robotics and Automation (ICRA), and the
International Conference on Intelligent Robots and Systems (IROS). He also owns two US
patents, two international patents, seven Chinese patents, with nine other US patents and
two Chinese patents pending. He also won the MICCAI 2006 Young Scientist Award. As an
entrepreneur, he was awarded as the Thousand Talents Plan in China.
**************************************************************** BioScience Forum, Wednesday Evening, Oct. 19, 2016 Topic: "Probody Therapeutics Enable Safer and More Effective Oncology Therapies" Speaker: Michael Kavanaugh, M.D., Chief Scientific Officer and Head of Research and Non-Clinical Development, CytomX Therapeutics Date and Time: Wednesday, Oct. 19, 2016 6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentation
Location: The Holiday Inn, 275 S Airport Blvd,South San Francisco, CA 94080
Next door to the SSF Conference Center
Price:
$50 before 9PM, Monday, October 17th
$60 on-site
$40 full-time students pre-registration
$50 full-time students on-site
$3 service fee will be added to the pre-registration price
Register at http://www.biosf.org/
Topic Description Probody™ therapeutics are fully recombinant antibody prodrugs that are converted to active antibodies by tumor-associated proteases. A Probody therapeutic is engineered by “masking” the antigen binding site of an antibody with a short recombinant extension of the light chain at its NH2-terminus, which interacts with the CDRs and physically blocks the ability of the antibody to bind target. Because of this masking, Probody therapeutics remain substantially inactive in normal tissues and in circulation. However, when the Probody therapeutic encounters a tumor, the mask is designed to be cleaved and removed by tumor-associated proteases, and the antibody becomes fully active within the tumor microenvironment. In this way, Probody therapeutics protect normal tissues while concentrating active antibody in tumors, widening the therapeutic index. CytomX has demonstrated that the Probody technology is applicable to multiple antibody-based therapies, including naked signal-blocking antibodies, antibody drug conjugates, T cell-engaging bispecifics and CAR-T or CAR-NK cells. This approach is particularly useful for potent antibody-based therapies whose clinical utility is limited by toxicity. For example, CytomX is developing Probody therapeutics directed to immune-oncology targets such as PD-L1 to enable the use of potent combination immune therapies that are currently difficult to use because of immune-related toxicities. Further, because
7
Probody therapeutics have limited interaction with target in normal tissues, Probody drug conjugates allow targeting of highly desirable, first-in-class tumor antigens that are expressed at very high levels in tumors but are not suitable for traditional antibody drug conjugates because they are also expressed in normal tissues and would be expected to result in unacceptable toxicity. Similarly, T cell-engaging bispecific antibodies (TCBs) bring together the very potent tumor killing mechanism of T cells with tumor antigens, but are very unforgiving for the presence of even small amounts of target on normal tissue. Probody therapeutics may allow the broader use of TCBs, particularly for solid tumors. Preclinical data demonstrating the utility of Probody therapeutics in each of these classes will be presented. CytomX is planning an IND for its first Probody therapeutic directed against PD-L1 by the end of the year, and an IND for a Probody drug conjugate directed against CD-166 in the first half of 2017. A full pipeline of additional candidates is being developed. PROBODY is a trademark of CytomX Therapeutics, Inc. Speaker Bio Michael Kavanaugh, M.D. joined CytomX in January 2015 as chief scientific officer and head of research and early development. Prior to joining CytomX, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics since 2009. Before Five Prime, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis in 2006 as part of the company’s acquisition of the Chiron Corporation, where he was vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his medical doctorate from Vanderbilt University and his bachelor’s degree in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at the University of California, San Francisco and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of medicine at UCSF. **********************************************************************************************************
CSLA, Tuesday, Oct. 25, 2016
Event: Evening With Thought Leaders
Date and Time: Tuesday, Oct. 25, 2016, 6:00 pm
Location: Sheraton Palo Alto 625 El Camino Real Palo Alto, CA 94301
Panel Discussions
Location: Sheraton Palo Alto, 625 El Camino Real, Palo Alto, CA 94301
Questions? Please contact [email protected].
Event Description
CLSA members have come to rely on this program as a way to stay current on trends in the
biomedical industry and get fresh insights from key opinion leaders on policy, economics,
business and society. Past speakers have included Former Secretary of State and
Distinguished Fellow at the Hoover Institution, Stanford University, George P. Schultz, the
Dean of Scripps School of Medicine and author of The Creative Destruction of Medicine, Dr.
Eric Topol, and the Distinguished Professor, from the UC San Diego Stem Cell program, Dr.
Larry Goldstein.
********************************************************************
HBA, Tuesday Evening, Oct. 25, 2016
Event: “Chocolate, Wine and Networking!”
8
Date and Time: Tuesday, October 25, 2016, 5:00 p.m. – 8:00 p.m. PST
5:00 p.m. – 6:00 p.m. Check-in and light snacks
6:00 p.m. – 6:45 p.m. Chocolate tasting and wine pairing
6:45 p.m. – 8:00 p.m. Networking
Location: Foley & Lardner LLP, 975 Page Mill Road, Palo Alto, CA 94304-1013
Registration Deadline
October 24, 2016
Walk-Ins Accepted?
Walk-ins are not accepted – be sure to register early!
Pricing Information
Members: $35
Non-Members: $55
Registration Deadline
October 24, 2016
Special Pricing for Guests
When registering, members are also allowed 1 guest at member pricing
Parking Information
Free parking is available.
Details and registration at http://www.womeninbio.org/eventdetails.aspx?EventId=30066
Description
Our Fall networking event is even sweeter this year! We are bringing back The Chocolate
Garage to delight us with their delicious artisan chocolate bars while we socialize with each
other. This event will provide an opportunity to reconnect with colleagues, bring a friend
who has expressed interest in joining, or check out WIB for the first time.
Light snacks will be provided.
Learn more and register for this event.
********************************************************************
HBA Webinar, Wednesday Evening, Oct. 26, 2016
Topic: “Advanced Practice Social Media”
Featured Speakers:
Lea Carey
Global market strategy lead, Symplur
Julie Kelly
Vice president, business development, Ashfield, par of UDG Healthcare plc
Kelley Connors
President, KC Health, and global chair, HBA Digital Innovators
Jessica Pfenning
Enterprise digital leader, AstraZeneca, global chair, Digital Innovators, HBA
In this hour, attendees will get a deeper understanding of the implications of their social
media profile, habits and behaviors, and how those concepts can affect and improve both
career and business opportunities. Also discussed will be selected HBA profiles from
members who are experts in leveraging their digital persona, and we'll try to answer an
increasingly modern day, technological issue: How do you meet peers and increase your
professional network online knowing that you may never meet them in person?
Date and Time: Wednesday, Oct. 26, 2016, 8:00 – 9:00 pm ET; 5:00 – 6:00 pm PT
8:00 – 8:03 PM ET Introduction
8:03 – 8:43 PM ET Presentation
8:43 – 8:58 PM ET Q&A
8:58 – 9:00 PM ET Close
9
Fees: Registration information
Event is open to: HBA members and nonmembers
Online registration available until one hour before the live broadcast begins.
Member rate:$25; Nonmember rate:$35
Register at https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=956055F2-D875-
E6...
Webinar description
Advanced Practice Social Media, presented by the HBA Digital Innovators affinity group, will
offer more insights and information for the sophisticated social media user.
In this hour, attendees will get a deeper understanding of the implications of their social
media profile, habits and behaviors, and how those concepts can affect and improve both
career and business opportunities. Also discussed will be selected HBA profiles from
members who are experts in leveraging their digital persona, and we'll try to answer an
increasingly modern day, technological issue: How do you meet peers and increase your
professional network online knowing that you may never meet them in person?
Lea Carey, global market strategy lead, Symplur and HBA global board member, will lead
this highly engaging and informative session that is meant to serve as first part of a two-
part webinar series. Lea will be joined by Julie Kelly, global chair, HBA Digital Innovators,
and Kelley Connors, president, KC Health, and global chair, HBA Digital Innovators, and
Jessica Pfennig, enterprise digital leader, global commercial, AstraZeneca, and global chair,
HBA Digital Innovators. The first, beginner to intermediate level webinar, How To Leverage
Social Media to Ignite Your Personal and Professional Success, will take place on
Wednesday, October 5 from 8:00 to 9:00 PM ET.
Learning objectives
1. Build upon current levels of social media presence.
2. Assess business opportunity implications of social media profile, habits and behaviors
*************************************************************************
JLABS, Thursday Afternoon, Oct. 27, 2016
Topic: “Accelerating Drug Discovery: Business Models for the Computational Pharmaceutical
Company”
Speakers:
Steve Quake | Co-Founder, Agenovenir read bio»
Matt Ocko | Co-Managing Partner & Co-Founder, DCVC read bio»
Max Hodak | CEO & Co-Founder, Transcriptic read bio»
Anthony Rowe | Director & Business Technology Leader for Immunology Therapeutic Area,
Janssen Human Microbiome Institute, Janssen Immunoscience & Janssen Prevention Centre
Date and Time: Thursday, October 27, 2016 from 3:00 PM to 6:30 PM (PDT)
Agenda:
3:00pm | Registration Opens and Networking
3:30pm | Introductions
3:35pm | Panel
5:00pm | Networking Reception
6:30pm | Program Close
Fees:
$25 | General Public
$35 | Onsite
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
10
Register at http://www.eventbrite.com/e/accelerating-drug-discovery-business-models-for-
the-computational-pharmaceutical-company-tickets-25860813389?aff=weekly
Event Details
What does it take to become a successful entrepreneur in the drug development space? The
landscape of life science startups is no longer composed solely of companies with small
molecule or biologic assets, but also includes machine learning technologies, platforms, and
software tools to accelerate the R&D process.
The current era of bioinformatics presents opportunities and challenges to both Big Pharma
and entrepreneurs alike. Johnson & Johnson Innovation, JLABS in cooperation with Data
Collective (DCVC), has assembled a distinguished panel of experts to address how
computational prowess can advance pharmaceutical development and shorten time to
market as well as the breadth of obstacles faced by modern bioinformatics.
Topics include:
What methods of partnering with Big Pharma have been most successful?
Which models (SaaS, milestone payments, royalties, etc.) work for which situations?
How are Software tools, bioinformatics, and data analyses increasing ROI for pharma R&D?
What is 'machine learning' and how can it be used to accelerate drug discovery?
Our panel discussions are candid, interactive and informal. We hope you walk away with
insights and knowledge that can help advance your work or overcome roadblocks. A
networking session will take place after the panel.
About Data Collective:
Data Collective is the first venture capital fund to invest exclusively in entrepreneurs
building companies in the areas of Big Data and deep compute. Big Data companies
capture, store, secure, transmit, transform, and analyze data for economic advantage,
either with huge volumes (terabytes to exabytes), at tremendous speed (microseconds to
seconds), or both.
According to a report by CB Insights, Data Collective was the most active investor in
artificial intelligence startups in 2015.
Data Collective draws on a fund of just under $1 billion and invests early in a startup's
development, focusing on Series Seed, Series A, and some select growth-stage companies.
The firm has a unique model composed of 50+ Equity Partners with diverse experience
ranging from academics at Stanford University to technical experts at Google and Twitter.
These leaders help diligence deals and provide technical and industry vertical expertise.
Additionally, a small set of Operating Partners with entrepreneurial experience also work
with the portfolio at a deeper level to guide them toward success. With these resources at
their disposal, Data Collective companies successfully raise subsequent rounds of capital
from Silicon Valley firms ~95% of the time.
Healthcare, the life sciences, and the pharmaceutical industry are natural fits for Big Data
technologies, which offer the potential for accelerated drug development, early diagnosis of
disease, identification of gaps in care, and other advancements to optimize the patient
experience and produce much more targeted, safe, and effective medicines. As such,
healthcare has been a specific area of focus for the firm, with roughly 25-30% of the
portfolio developing solutions in multiple areas of the healthcare ecosystem.
Data Collective has offices in San Francisco and Palo Alto, California. The firm's two
founding and co-Managing Partners, Zachary Bogue and Matt Ocko, are deeply technical
and are seasoned entrepreneurs, inventors, and venture capitalists.
Speaker Bios
11
Steve Quake | Co-Founder, Agenovenir
Stephen Quake studied physics (BS 1991) and mathematics (MS 1991) at Stanford
University, after which he earned a doctorate in theoretical physics from Oxford University
(1994) as a Marshall Scholar. He then returned to Stanford University, where he spent two
years as a postdoc in Steven Chu's group. Quake joined the faculty of the California
Institute of Technology in 1996, where he rose through the ranks and was ultimately
appointed the Thomas and Doris Everhart Professor of Applied Physics and Physics. At
Caltech, Quake received "Career" and "First" awards from the National Science Foundation
and National Institutes of Health and was named a Packard Fellow. These awards supported
a research program that began with single molecule biophysics and soon expanded to
include the inventions of single molecule sequencing and microfluidic large scale integration,
and their applications to biology and human health. He moved back to Stanford University
in 2005 to help launch a new department in Bioengineering, where he is now the Lee
Otterson Professor and an Investigator of the Howard Hughes Medical Institute. Quake's
contributions to the development of new biotechnology at the interface between physics and
biology have been widely recognized. Honors include the Human Frontiers of Science
Nakasone Prize, the MIT-Lemelson Prize, the Raymond and Beverly Sackler International
Prize in Biophysics, the American Society for Microbiology Promega Biotechnology Research
Award, the Royal Society of Chemistry Publishing Pioneer of Miniaturization Award, and the
NIH Director's Pioneer Award. He is an elected fellow of the American Academy of Arts and
Sciences, the National Academy of Inventors, the National Academy of Sciences, the
National Academy of Engineering, the Institute of Medicine, the American Institute for
Medical and Biological Engineering and of the American Physical Society.
^ Back to speakers' list ^
Matt Ocko | Co-Managing Partner & Co-Founder, Data Collective Venture Capital (DCVC)
Matt Ocko, co-Managing Partner and co-founder of Data Collective (DCVC), has three
decades of experience as a technology entrepreneur and VC, in the US and globally. In
addition to large IPO outcomes, many of Matt's prior investments were acquired to become
core capabilities of companies like Illumina, Cisco, Google, IBM, Amazon, and Akamai. He
was also an early investor in Facebook (FB), Uber, AngelList, and Zynga (ZNGA). Matt's
current investments in next generation bioinformatics, genomics, synthetic biology, and
robotics and AI to accelerate discoveries in these fields include Transcriptic, Atomwise,
Nervana, Zymergen, Vicarious, 3Scan, Diassess, D-Wave, Rigetti Quantum Computing,
Scaled Inference, Ginkgo Bioworks, and several other large-scale but stealth companies.
Matt holds a degree in Physics from Yale University, and he is an inventor on over 40
granted or in-process patents in areas ranging from computer systems virtualization to
fraud detection. He has been active on a pro-bono basis in helping develop China's venture
capital and technology regulatory framework for two decades.
Connect with Matt: Connect on LinkedIn
Max Hodak | CEO & Co-Founder, Transcriptic
Transcriptic is a robotic cloud laboratory for biology. We design, build, own and operate an
automated molecular and cell biology infrastructure from our facility in Menlo Park, CA that
scientists access remotely via a web browser over the internet. Our customers range from
academic labs at Stanford, Harvard, UCSF, UCSD and more, to startups, to large
biopharma. Our mission is to enable anyone to start and run a biotech company from a
coffee shop with only a laptop, and enable individual scientists to achieve scale never before
possible. Max studied biomedical engineering at Duke and worked in a lab studying
multiunit electrophysiology in rhesus monkeys to build brain-machine interfaces. He started
a company called MyFit to help match students and colleges (which resulted in a two year
12
detour from college through Silicon Valley) that was sold to Naviance. At Transcriptic he is
working on building better tools for scientists.
Anthony Rowe, Ph.D. | Director & Business Technology Leader for Immunology Therapeutic
Area, Janssen Human Microbiome Institute, Janssen Immunoscience & Janssen Prevention
Centre
Dr Anthony Rowe is currently a Business Technology Leader at Janssen Research and
Development where he is responsible for defining the digital strategy for the Janssen's
Immunology Therapeutic Area, ImmunoScience Centre of Excellence, Disease Prevention
Centre and Human Microbiome Institute. He is passionate about Digital Health and Precision
Medicine and its use in developing patient centric healthcare solutions. Prior to joining
Janssen he was a Director of Product Management & Founding Member of InforSense Ltd an
innovative big data analytics company that provided Pharmaceutical, Financial Services and
Telecommunication customers access to machine learning and high performance computing
technology. During his tenure at Inforsense he had roles leading Engineering, Marketing,
Technical Sales as well as Product Management and was involved in both fund raising,
growing the company from 7 to 150 people and a successful exit of the company. Dr Rowe
holds a PhD in Computer Science and an MSc in Artificial Intelligence from Imperial College
London and a BEng in Computer Systems Engineering from the University of Warwick.
*****************************************************************
PBSS, Friday, Oct. 28, 2016
Event: Minisymposium: Immuno-Oncology Biomarkers: Fundamentals, Technologies, and
Applications in the Development of Cancer Therapeutics
Speakers: Scott Patterson PhD (Gilead), Terri McClanahan PhD (Merck), Rod Prell PhD
(Genentech), Michael Angelo MD PhD (Stanford), Luciana Molinero PhD (Genentech), Take
Ogawa (Second Genome) , Adil Daud MD (UCSF), Jeff Wallin PhD (Genentech), Jakob
Dupont MD (Onco
Date and Time: Friday, October 28, 2016, 8:45-17:30
Agenda:
1. Biomarkers in cancer drug development - Scott Patterson, PhD
2. Maximizing the Benefit of Anti-PD1 Therapy - Terri McClanahan, PhD
3. Safety biomarker in pre-clinical models - Rod Prell, PhD
4. Analysis of the tumor microenvironment using high dimensional IHC and multiplexed
ion beam imaging - Michael Angelo, PhD
5. Biomarker for breast cancer immunotherapy - Luciana Molinero, PhD
6. Microbiome for oncology drug discovery and development - Take Ogawa, PhD
7. Biomarker strategy for combination immunotherapy - Jeff Wallin, PhD
8. Novel T cell biomarkers for response to PD1 and PD1/CTLA4 immunotherapy - Adil
Daud, MD
9. Biomarkers for novel Immune Checkpoint inhibitors - Jakob Dupont, MD
Registration fee (US$): Minisymposium fee: $195; For others, details available upon online
login.
Location: Crowne Plaza, Foster City, CA
Registration: http://www.PBSS.org
Registration deadline: 10/26/2016 (it will close sooner if the seating cap is reached) ************************************************************************************** ASQ Course, Friday Morning, Nov. 4, 2016 Event: “B113 - Preparing & Submitting 510K's & PMA's”
13
Instructor: Patrick Lee
Date and Time: Friday, Nov. 4, 2016, 8:00 am – 12:oo pm Location: International Technological University 2711 North First Street San Jose, CA 95134 Instructor is Patrick Lee Registration at Registration at https://goo.gl/MXoXNh Overview • US Regulation history and overview • Medical Device Users Fee and Modernization Act (MDUFMA) • Medical Device Classification • Key terms and elements • FDA regulatory pathways • When 510(k) is required • Types of 510(k)s • Planning and executing a 510(k) • The FDA 510(k) review process • When to submit a 510(k) for a changed device
• When a PMA is required • Types of PMAs • Planning and executing a PMA • Points to consider • The FDA PMA review process • PMA Supplements • Other worldwide regulatory bodies and authority • Regulatory compliance issues overviewo Benefits This course covers materials that are essential to those individuals who are interested in medical device submissions to the FDA and presents an overview of regulatory pathways for medical devices in the U.S. with a focus on the FDA 510(k) process including IDE, PMA, HDE, de novo 510(k), combination products, and CE Marks. Soly Paterson ASQ CMQ/OE Course Coordinator ASQ Silicon Valley - Section 0613 [email protected]|408.410.3934 **************************************************************************************
JLABS, Tuesday Mid Day, Nov. 15, 2016
Topic: “Out of the Lab and into the Newsroom”
Speakers:
Carin Canale-Theakston | President and Founder, Canale Communications read bio»
Victoria Colliver | Health Reporter, San Francisco Chronicle read bio»
Michael Fitzhugh | Staff Writer, BioWorld Today read bio»
Ron Leuty | Biotech Reporter, San Francisco Business Times read bio»
Susan Schaeffer | Editor, BioCentury read bio»
Date and Time: Tuesday, November 15, 2016 from 11:30 AM to 2:30 PM (PST)
Agenda:
11:30 AM | Registration Opens, Lunch, and Networking
12:00 PM | Panel Discussion
1:00 PM | Hands-on Working session
1:45 PM | Story Pitching
2:30 PM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco,
California
Fees:
$35 | General Public
$20 | Student/Academic
$45 | At the door
14
Topic Description
Anxious at the thought of interacting with the media? Our all-star lineup of reporters
is back, bringing you tips straight from the source on the right way to get your story
out there.
You've got your cutting-edge technology, you've raised money, and your company is
making some great headway on the R&D front. You're ready to bring your company
out of stealth mode and into the limelight, but you don't know how. In this three-part
workshop event, we'll explore how to take your story out of the laboratory and into
the headlines:
First, a panel of industry reporters will provide insight into how they like to be
pitched, what makes something "newsworthy" and what they are looking for to
include in coverage.
Second, in a working session, seasoned communications professionals will help you
craft your story using a framework that works well for telling life science stories that
resonate with multiple audiences.
Finally you'll have a chance to pitch the reporters in attendance who will each select
one company that will be the subject of a one-on-one background interview at a later
date.
Key topics will include:
What makes a story "newsworthy"?
What's the best way to pitch a reporter?
How do you translate complex science into a story others can understand?
Tips for your interview
The workshop will be led by life science communication expert, Carin Canale-
Theakston, president and founder of Canale Communications.
Speaker Bios
Carin Canale-Theakston | President and Founder, Canale Communications
Carin Canale-Theakston is the president and founder of Canale Communications Inc.
In her role as president, Carin works closely with client teams, having provided
senior level strategy to more than 125 life science companies of all shapes and sizes
ranging from pre-series A financing to billion dollar public companies such as Amgen
and Johnson & Johnson. Through her career in life science communications, she has
advised a diverse range of companies including biotechnology, biopharmaceutical,
medical device, diagnostics, research organizations and providers of enabling
technologies.
In addition to client services, Carin is actively involved in the life science community.
She is currently the vice chairwoman of the board of directors for BIOCOM, Southern
California's life science trade association, and a member of the board of directors for
the San Diego Venture Group. She is also a trustee of the Mission Hills Town Council
and a member of the board for A Note to My Kid, a non-profit organization for gay
and lesbian youth. A sought-after speaker, Carin frequently leads presentations and
trainings on various communication topics for these organizations and others such as
PRSA, the Biotechnology Industry Organization and California Healthcare Institute.
Prior to founding Canale Communications, Carin was president of the life sciences
division of international public relations firm Porter Novelli, managing teams in San
Diego, Los Angeles, Boston and New York. Carin joined Porter Novelli when the firm
acquired boutique life sciences communication firm, Atkins + Associates, in which
Carin was partner and managing director. Carin also held various positions for
several agencies including Townsend Inc., Littlefield Communication and Burson-
Marstellar. Before becoming engrossed in the agency world, Carin served as
15
community relations director for a non-profit organization (Domestic Violence
Intervention Services), where she generated global awareness, managed a national
speaking circuit and supported the company's fundraising efforts.
Carin holds a bachelor of arts from the University of Tulsa with a major in
communications and a minor in marketing.
Victoria Colliver | Health Reporter, San Francisco Chronicle
Bio coming soon!
Michael Fitzhugh | Staff Writer, BioWorld Today
Michael Fitzhugh joined the BioWorld team as a staff writer in 2014. He has
contributed to and edited several in-depth annual reports about health care's ever
changing landscape as an editor in Burrill & Co.'s San Francisco-based media group
while reporting about biopharma's unfolding story. Prior to that, he covered
biotechnology and high tech companies for American City Business Journals. He
received his MJ from the University of California at Berkeley's Graduate School of
Journalism and holds a BA from the University of Michigan. When unplugged from
reporting, he enjoys spending time with his young children and playing fiddle in
Berkeley, Calif.
Ron Leuty | Biotech Reporter, San Francisco Business Times
Ron Leuty has been a reporter or editor for more than 25 years, including editor of
two startup business journals and business editor of the Prague Post in the Czech
Republic. He has covered biotech for the San Francisco Business Times for eight
years. He also has covered banking, manufacturing, law and sports business.
Susan Schaeffer | Editor, BioCentury
Susan serves as Editor of BioCentury. She has been reporting and commenting on the
biopharmaceutical industry for 11 years, covering drug discovery and development,
corporate strategy and finance, and regulation and policy as it affects multiple
stakeholders in the biomedical ecosystem. Her work has been cited in regulatory
filings and has recently influenced biopharma executives to pursue legislative
changes necessary to enable greater experimentation with pricing models designed to
make innovation more affordable to healthcare systems.
She was previously Senior Editor in charge of Product Discovery & Development
coverage from 2010 through 2012. She was Managing Editor of BioCentury and
BioCentury Extra from 2004 through 2010. She joined BioCentury in 2003 after 10
years as an editor in the consumer packaged goods sector, including work with
international strategy consultants Kurt Salmon Associates.
*********************************************************************
